High Growth Tech Stocks To Watch In The US March 2025

Over the last 7 days, the United States market has experienced a 4.6% drop, yet it remains up by 8.8% over the past year with earnings projected to grow by 14% annually. In this context of fluctuating performance and promising growth forecasts, identifying high-growth tech stocks involves focusing on companies with strong innovation potential and robust financial health that can capitalize on these market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Aldeyra Therapeutics (NasdaqCM:ALDX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of $379.15 million.

Operations: Aldeyra Therapeutics focuses on developing and commercializing treatments for immune-mediated diseases. The company operates within the biotechnology sector, with a market capitalization of approximately $379.15 million.

Aldeyra Therapeutics, despite its current unprofitability and minimal revenue under $1 million, is positioned for significant growth with expected annual revenue increases of 41.4% and earnings growth forecasted at 55.5%. This ambitious growth trajectory outpaces the general US market's average of 8.4% and aligns with projections that see the company turning profitable within three years. Recent strategic movements include a new shelf registration aimed at bolstering financial flexibility and presentations at major healthcare conferences, signaling active engagement in expanding its market presence and investor relations. These steps could catalyze Aldeyra’s transition from a high-potential firm to a profitable entity in the burgeoning biotech sector.

• Click to explore a detailed breakdown of our findings in Aldeyra Therapeutics' health report.

• Understand Aldeyra Therapeutics' track record by examining our Past report.

Blackbaud (NasdaqGS:BLKB)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Blackbaud, Inc. provides cloud software and services both in the United States and internationally, with a market capitalization of approximately $3.18 billion.

Operations: The company generates revenue primarily through its Software & Programming segment, which accounts for $1.16 billion.

Blackbaud's recent financial performance and strategic initiatives underscore its evolving role in the tech landscape, despite a challenging year with a net loss reported at $286.95 million for 2024 compared to minimal net income previously. The firm is actively expanding its technological capabilities, notably through integrating cryptocurrency donations in the U.S., enhancing its appeal to modern donors and potentially boosting future revenue streams. This move complements their significant R&D investment, which remains crucial as they navigate through profitability challenges. Moreover, Blackbaud's repurchase of shares worth $586.38 million since 2010 reflects a strong commitment to shareholder value amidst fluctuating earnings forecasts expected to grow by 59.3% annually over the next three years—a testament to their strategic long-term vision in the competitive software sector.

• Delve into the full analysis health report here for a deeper understanding of Blackbaud.

• Gain insights into Blackbaud's historical performance by reviewing our past performance report.

Blend Labs (NYSE:BLND)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Blend Labs, Inc. provides cloud-based software platform solutions for financial services firms in the United States and has a market cap of approximately $800.34 million.

Operations: The company generates revenue primarily through its Blend Platform, which accounted for $115.76 million, while Title services contributed $46.26 million.

Blend Labs has demonstrated resilience and adaptability in the tech sector, notably improving its financials with a year-over-year revenue increase from $156.85 million to $162.02 million. This growth is complemented by a significant reduction in net loss, down from $178.69 million to $43.35 million, reflecting effective cost management and operational efficiency. The firm's commitment to innovation is evident in its recent partnership with Truework, enhancing its consumer banking products by integrating advanced verification technologies that streamline lending processes and improve customer experience. This strategic move not only addresses current market needs but positions Blend Labs favorably as it navigates future industry challenges, potentially setting the stage for sustained growth amid evolving digital lending landscapes.

• Dive into the specifics of Blend Labs here with our thorough health report.

• Explore historical data to track Blend Labs' performance over time in our Past section.

Next Steps

• Discover the full array of 235 US High Growth Tech and AI Stocks right here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com